Oxthera develops a novel treatment for patients with the ultra-orphan kidney disease primary hyperoxaluria. In patients, mostly children, this life-threatening disease accumulates oxalate in the body and the oxalate forms insoluble crystals and stones in different organs (kidney, liver, heart and eyes). There is no treatment for primary hyperoxaluria and the patients enter end-stage-renal dialysis within a few years.

Oxthera’s therapy introduces live bacteria that consume the accumulated oxalate in the gut and in the organs and reduces the necessity for dialysis and liver-kidney transplantations. Oxthera is currently running a placebo-controlled phase III with selected patients in several countries.

The company has a strong management team and is backed by number of well-known international venture capital investors.